Identifying cognitive mechanisms targeted for treatment development in schizophrenia: an overview of the first meeting of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia Initiative.
about
Toxoplasma gondii infection, from predation to schizophrenia: can animal behaviour help us understand human behaviour?Leveraging the cortical cholinergic system to enhance attentionCNTRICS final task selection: executive controlA Hierarchical Generative Framework of Language Processing: Linking Language Perception, Interpretation, and Production Abnormalities in SchizophreniaSynaptic plasticity, neural circuits, and the emerging role of altered short-term information processing in schizophrenia.Future clinical uses of neurophysiological biomarkers to predict and monitor treatment response for schizophreniaProof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophreniaInnovative solutions to novel drug development in mental healthRemoving obstacles in neuroscience drug discovery: the future path for animal models.Haploinsufficiency of the 22q11.2 microdeletion gene Mrpl40 disrupts short-term synaptic plasticity and working memory through dysregulation of mitochondrial calcium.Reduced Prepulse Inhibition as a Biomarker of Schizophrenia.Atypical visual and somatosensory adaptation in schizophrenia-spectrum disorders.Auditory tasks for assessment of sensory function and affective prosody in schizophrenia.Impaired limbic cortico-striatal structure and sustained visual attention in a rodent model of schizophrenia.Activation of nociceptin/orphanin FQ peptide receptors disrupts visual but not auditory sensorimotor gating in BALB/cByJ mice: comparison to dopamine receptor agonists.Assessment of glutamate transporter GLAST (EAAT1)-deficient mice for phenotypes relevant to the negative and executive/cognitive symptoms of schizophrenia.Cognitive control deficits in schizophrenia: mechanisms and meaningEmotional response deficits in schizophrenia: insights from affective science.Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia.Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far?What happens in the brain of schizophrenia patients?: an investigation from the viewpoint of neuropathology.Altered brain activation during action imitation and observation in schizophrenia: a translational approach to investigating social dysfunction in schizophrenia.The puzzle of schizophrenia: tracking the core role of cognitive deficits.CNTRICS final task selection: social cognitive and affective neuroscience-based measures.Factor structure of the neurocognitive tests: an application of the confirmative factor analysis in stabilized schizophrenia patientsCognition in mouse models of schizophrenia susceptibility genes.Effects of domain-specific noise on visual motion processing in schizophrenia.Transcranial magnetic stimulation: a neuroscientific probe of cortical function in schizophrenia.Pharmacological or genetic inactivation of the serotonin transporter improves reversal learning in mice.Brain mapping biomarkers of socio-emotional processing in schizophrenia.Predictably irrational: assaying cognitive inflexibility in mouse models of schizophrenia.Thinking about the future cognitive remediation therapy--what works and could we do better?Functional neuroimaging of treatment effects in psychiatry: methodological challenges and recommendationsIdentifying cognitive remediation change through computational modelling--effects on reinforcement learning in schizophreniaComputational psychiatry.Lurasidone: a new drug in development for schizophrenia.Schizophrenia and tobacco smoking comorbidity: nAChR agonists in the treatment of schizophrenia-associated cognitive deficits.Early sensory contributions to contextual encoding deficits in schizophrenia.Abnormal negative feedback processing in first episode schizophrenia: evidence from an oculomotor rule switching taskDo GluA1 knockout mice exhibit behavioral abnormalities relevant to the negative or cognitive symptoms of schizophrenia and schizoaffective disorder?
P2860
Q22306157-902FC159-12AD-4FD7-AC0C-EF9106E9B04DQ24598925-9CD5EE0E-CFB7-4B00-B9DC-A41F7191C4A5Q24651882-C8EE9BDB-2FFF-4CFB-9697-7E90A4DCBE7FQ26774145-8091B17D-6D93-4F05-A744-DAB59B62C449Q26829347-72254A99-4CC1-4737-8C54-EBA8A9EA8231Q27014120-74563B0E-6DB0-41F1-BEE2-BF8557444C57Q28240120-FCAFA2D5-6BEA-4182-8F87-391F273DFA95Q28677399-43C15F29-466D-4D98-A14D-377515729E8FQ28755229-E79862FF-1BE7-470F-A15D-72CE88BA949FQ30369603-46838B46-8BEB-48E3-A0A4-E0BF0CE80502Q30370952-920FA430-7A97-4E11-8C81-E79272C85602Q30372221-7CABA13B-9D54-4BF1-B8DC-B11BCA47B680Q30395367-D97783B3-B155-47D2-86E6-903D58C943AFQ30403790-E86297AA-C1BC-4484-BDA3-51047D630963Q30459631-D6E8592D-E668-4AD8-87C9-C9D7D8B57EF4Q30465586-E26C1A24-376E-49C1-A83F-27B45B4EB48AQ30476447-1A8C4262-72E5-4450-BA93-C771E0413BD5Q30487306-A8BAA0A8-DE09-4F03-AECE-7DC67EA7EF34Q30489404-F67C3874-0085-461B-96F2-822F5E06AA8DQ30536299-BF328950-D620-47A6-A9B2-D50A54840717Q30610218-A8DBAD8A-4B27-4135-8EC6-0053DC8292FEQ30665165-84808E9F-73F8-4577-AA6E-48A8E6491A83Q33353490-752E70D8-DCE5-4AFF-860F-910A930D2E06Q33384618-F30636DA-FA7B-4403-A94F-2BC2DD5A6A34Q33610028-BA5C34BD-39E1-4558-95C0-F10E9A22C9B9Q33707698-4FE3C6FA-7A56-4DEF-A927-ACA93F476F13Q33734083-26168A97-EC9E-497A-90B9-2FC2AA3F346AQ33899682-D9C26DEE-71D5-4542-B911-2A76CBA5696DQ34030543-3898DBF1-17C6-4E69-8A06-9BD9BB280A22Q34037481-1704EEF2-C2B1-42DA-AB3A-D679219B6BE9Q34125605-F1D17732-70DC-4274-A9BF-01881B25B581Q34210022-48755DC6-545E-494E-8825-65A32C5F68C2Q34218300-FEC0EB5B-9348-4D94-B96D-0918887ADBBDQ34322887-5F93CFDA-3F49-4BF0-B546-50D6083C289DQ34630298-0D6C94C3-2D01-4188-AC46-DAE0DF25ADF3Q35005165-B417BD4B-8DCD-4BCF-B7B9-543FE4B37460Q35048154-1204C959-05FA-4933-9E5B-B7BB90861998Q35136571-A71CA46D-47B1-42FC-92E3-CFF0181CBDFAQ35159829-03F809A5-8BED-4DBC-A1F4-31050108352BQ35522856-D5A2324E-0655-40EF-B2AB-8C513CAD57F9
P2860
Identifying cognitive mechanisms targeted for treatment development in schizophrenia: an overview of the first meeting of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia Initiative.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Identifying cognitive mechanis ...... n in Schizophrenia Initiative.
@en
type
label
Identifying cognitive mechanis ...... n in Schizophrenia Initiative.
@en
prefLabel
Identifying cognitive mechanis ...... n in Schizophrenia Initiative.
@en
P2093
P2860
P50
P1476
Identifying cognitive mechanis ...... n in Schizophrenia Initiative.
@en
P2093
Cameron S Carter
Edward E Smith
John H Krystal
Jonathan Cohen
Mark Geyer
Milton Strauss
Robert Heinssen
Robert W Buchanan
Steven Silverstein
P2860
P356
10.1016/J.BIOPSYCH.2008.03.020
P407
P50
P577
2008-05-07T00:00:00Z